This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

CohBar (CWBR) Stock Overview

A clinical stage biotechnology company, develops mitochondria and peptides based therapeutics for the treatment of chronic and age-related diseases. More details

CWBR fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Risk Analysis

Does not have a meaningful market cap ($1M)

Latest financial reports are more than a year old

Volatile share price over the past 3 months compared to the US market

CWBR Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

CohBar, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for CohBar
Historical stock prices
Current Share Price	US$0.41
52 Week High	US$1.01
52 Week Low	US$0.000001
Beta	0
1 Month Change	-25.45%
3 Month Change	-18.00%
1 Year Change	-47.13%
3 Year Change	-95.73%
5 Year Change	-99.40%
Change since IPO	-99.02%

Recent updates

Seeking Alpha • Sep 22

CohBar stock gains on 1-for-30 reverse stock split

CohBar (NASDAQ:CWBR) shares gained 16% premarket on Thursday after the biotech firm announced a 1-for-30 reverse stock split of its common stock. The move is intended to enable the company to regain compliance with the Nasdaq $1.00 minimum bid price requirement. The reverse stock split will become effective at 12:01am ET on Sep 23, 2022 and begin trading on a split-adjusted basis at the market open on Sep 23, 2022. Concurrent with the approval of the reverse stock split, the shareholders also approved an effective increase in the number of authorized shares of the company's common stock. Subsequent to the reverse stock split and adjusting for the effective increase in authorized shares, there will be ~12M shares of common stock authorized for issuance.

Analysis Article • Jun 13

Here's Why We're Watching CohBar's (NASDAQ:CWBR) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

Shareholder Returns

	CWBR	US Biotechs	US Market
7D	0%	1.3%	1.4%
1Y	-47.1%	31.4%	25.7%

Return vs Industry: CWBR underperformed the US Biotechs industry which returned -3.7% over the past year.

Return vs Market: CWBR underperformed the US Market which returned 24.9% over the past year.

Price Volatility

Is CWBR's price volatile compared to industry and market?
CWBR volatility
CWBR Average Weekly Movement	15.7%
Biotechs Industry Average Movement	10.5%
Market Average Movement	7.2%
10% most volatile stocks in US Market	16.8%
10% least volatile stocks in US Market	3.1%

Stable Share Price: CWBR's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: CWBR's weekly volatility has decreased from 8894583% to 16% over the past year, but is still higher than 75% of US stocks.

About the Company

Founded	Employees	CEO	Website
2007	n/a	n/a	www.cohbar.com

CohBar, Inc., a clinical stage biotechnology company, develops mitochondria and peptides based therapeutics for the treatment of chronic and age-related diseases. It develops CB4211, a therapeutic that is in Phase 1a/1b clinical trial for the treatment of nonalcoholic steatohepatitis and obesity; and CB5138 Analogs, which is in preclinical study to treat idiopathic pulmonary fibrosis and other fibrotic diseases. CohBar, Inc. was incorporated in 2007 and is based in Menlo Park, California.

CohBar, Inc. Fundamentals Summary

How do CohBar's earnings and revenue compare to its market cap?
CWBR fundamental statistics
Market cap	US$1.19m
Earnings (TTM)	-US$12.69m
Revenue (TTM)	n/a

0.0x

P/S Ratio

0.0x

P/E Ratio

Is CWBR overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CWBR income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$12.69m
Earnings	-US$12.69m

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	0
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0.0%

How did CWBR perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/01/26 04:03
End of Day Share Price	2025/01/06 00:00
Earnings	2023/06/30
Annual Earnings	2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

CohBar, Inc. is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Nathan Weinstein	Aegis Capital Corporation
Kumaraguru Raja	Brookline Capital Markets
Michael Morabito	Chardan Capital Markets, LLC

This company listing is no longer active

CohBar (CWBR) Stock Overview

Risk Analysis

CohBar, Inc. Competitors

Revelation Biosciences

Scorpius Holdings

SQZ Biotechnologies

Windtree Therapeutics

Price History & Performance

Recent News & Updates

CohBar, Inc.(OTCPK:CWBR) dropped from S&P TMI Index

CohBar, Inc.(OTCPK:CWBR) dropped from NASDAQ Composite Index

Morphogenesis, Inc. cancelled the acquisition of CohBar, Inc. (NasdaqCM:CWBR) in a reverse merger transaction.

New major risk - Share price stability

Morphogenesis, Inc. and Cohbar, Inc. Announce Positive Results from Phase 1B Trial of Ifx-Hu2.0, A Novel Personalized Cancer Vaccine, in Checkpoint Inhibitor Resistant Advanced Merkel Cell Carcinoma and Cutaneous Squamous Cell Carcinoma

Morphogenesis, Inc. entered into a definitive agreement to acquire CohBar, Inc. (NasdaqCM:CWBR) for approximately $130 million in a reverse merger transaction.

Recent updates

CohBar, Inc.(OTCPK:CWBR) dropped from S&P TMI Index

CohBar, Inc.(OTCPK:CWBR) dropped from NASDAQ Composite Index

Morphogenesis, Inc. cancelled the acquisition of CohBar, Inc. (NasdaqCM:CWBR) in a reverse merger transaction.

New major risk - Share price stability

Morphogenesis, Inc. and Cohbar, Inc. Announce Positive Results from Phase 1B Trial of Ifx-Hu2.0, A Novel Personalized Cancer Vaccine, in Checkpoint Inhibitor Resistant Advanced Merkel Cell Carcinoma and Cutaneous Squamous Cell Carcinoma

Morphogenesis, Inc. entered into a definitive agreement to acquire CohBar, Inc. (NasdaqCM:CWBR) for approximately $130 million in a reverse merger transaction.

High number of new and inexperienced directors

CohBar, Inc. to Report Q3, 2022 Results on Nov 08, 2022

CohBar stock gains on 1-for-30 reverse stock split

CohBar, Inc. to Report Q2, 2022 Results on Aug 15, 2022

CohBar Appoints Effie Tozzo, Ph.D. to Its Board of Directors

Here's Why We're Watching CohBar's (NASDAQ:CWBR) Cash Burn Situation

CohBar Announces Extension of Nasdaq Compliance Period

CohBar, Inc. to Report Q1, 2022 Results on May 16, 2022

Price target decreased to US$2.17

High number of new and inexperienced directors

CohBar, Inc., Annual General Meeting, Jun 15, 2022

High number of new and inexperienced directors

Price target decreased to US$5.63

Independent Director recently bought US$96k worth of stock

CohBar Announces Positive Topline Results from the Phase 1a/1b Study of CB4211 Under Development for NASH and Obesity

High number of new directors

CohBar, Inc. Provides Update on the Phase 1a/1b Clinical Trial for CB4211 Under Development for NASH and Obesity

CohBar, Inc.(NasdaqCM:CWBR) dropped from Russell 3000E Index

CEO & Director Steven Engle has left the company

Price target decreased to US$6.10

CohBar, Inc. Announces the Selection of CB5138-3

New 90-day high: US$1.65

CohBar, Inc. Announces Preclinical Collaboration with NIAID to Evaluate Potential of CB5064 Analogs for Treatment of COVID-19 ARDS

New 90-day high: US$1.54

CohBar, Inc. Confirms Efficacy of Novel Apelin Agonists in Acute Respiratory Distress Syndrome Model

New 90-day high: US$1.21

CohBar, Inc. to Report Q3, 2020 Results on Nov 16, 2020

CohBar, Inc. Announces New Preclinical Data Demonstrating That Combination of A Cb5138 Analog with nintedanib

CohBar, Inc. has completed a Composite Units Offering in the amount of $15.006 million.

CohBar, Inc. to Report Q2, 2020 Results on Aug 13, 2020

Shareholder Returns

Price Volatility

About the Company

CohBar, Inc. Fundamentals Summary

Earnings & Revenue

Company Analysis and Financial Data Status

Data Sources

Analysis Model and Snowflake

Industry and Sector Metrics

Analyst Sources